MRA is the noninvasive imaging of choice, with rare contraindications, including ferromagnetic metallic implants and pacemakers. MRA can be performed as gadolinium 
A neurysm treatment is dedicated to prevention of rupture (for unruptured aneurysms) or rebleeding (for ruptured aneurysms). Endovascular embolization has become the firstline treatment for intracranial aneurysms in the majority of cases in many institutions. This minimally invasive approach achieved lower morbidity and mortality rates when compared with surgical management. [1] [2] [3] [4] However, although successful in improving patient care, its durability has been noted to be its Achilles' heel since the earliest application of this technology. Indeed, after endovascular treatment (EVT) ≈20% of patients will experience aneurysm or neck reopening after traditional endovascular coiling, necessitating retreatment in about half of them to maintain long-term protection over bleeding. 5 Despite this issue, low rates of bleeding have been reported after EVT of ruptured aneurysms, and its clinical superiority over surgery seems to be maintained over time according to the longterm clinical follow-up of the International Subarachnoid Aneurysm Trial (ISAT) cohort. 6, 7 In the Cerebral Aneurysm Rerupture after Treatment (CARAT) study, the bleeding rate after coil embolization was 0.11% (mean follow-up time, 4.4 years), whereas in the International Subarachnoid Aneurysm Trial, the annual risk of bleeding after coil-treated aneurysms was 0.08%. 8 In a large single-center study, the Barrow Ruptured Aneurysm Trial (BRAT), no bleeding was observed after 6 years in the coiling arm, but 4.6% of these patients were retreated. 9 Thus, one may question the clinical usefulness of performing imaging follow-up, balancing the small risk of bleeding after EVT with the cost-effectiveness of follow-up.
Although the primary end points of these studies were clinical, it is important to note that the majority of EVT patients had imaging follow-up performed at the discretion of the treating physician. For example, in the ISAT trial, 88.2% of the patients in the EVT arm (881 patients) had follow-up angiograms, generally performed 6 months after treatment and repeated at varying intervals. 10 Moreover, during the follow-up of the patients enrolled in these studies, it was noticed that some patients underwent retreatment without any bleeding, so that bleeding may have been more common if these aneurysms were not followed. 11 For example, 8.3% of the EVT patients in ISAT received late retreatment without prior rebleeding, whereas only 0.6% of them were retreated lately because of rebleeding. 10 Several mechanisms have been proposed to explain aneurysm recurrence, including coil compaction, aneurysm growth, coil migration through the aneurysm wall, coil penetration into the thrombus material of a partially thrombosed aneurysm, and abnormal inflammatory reaction of the aneurysm wall leading to growth. 12 Because recurrence is the main weakness of EVT, innovative technologies have been developed during the past decade to improve the long-term stability of EVT. New technologies were developed to improve aneurysm occlusion and coil density within the aneurysm sac and to treat complex aneurysms (large and/or wide-neck and/or bifurcation aneurysms) often prone to recur after simple coil embolization. 13, 14 Several options became progressively available in addition to standard coil embolization with bare platinum coils, widening considerably the treatment options the neurointerventionist can offer: surface-modified coils (such as polyglycolic/polylactic acid coated coils or hydrogel coated coils), balloon-assisted coiling, stent-assisted coiling, flow diverters, and recently flow disrupters. 15 Each treatment option has its own advantages and drawbacks. The physical properties of the material used will be crucial to determine the best modality for performing the follow-up.
Another concern for all patients harbouring an intracranial aneurysm is the appearance of newly detected (ie, de novo) aneurysms in ≈5% to 10% of patients. 16, 17 However, although many of them will be of small size, some will carry enough risk of bleeding to require treatment. 17 Then, imaging must be able to detect and follow them.
The possibility of aneurysm recurrence and of newly detected aneurysms, with the idea of providing an early
Stroke

May 2016
preventive treatment if necessary, justify imaging follow-up after EVT. This is all the more important as many individuals with coiled intracranial aneurysms have a potentially long life expectancy (for example, the mean age at entry into the ISAT trial was 52 years).
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A routine major concern for the patient is to know and understand when, for how long, and how the follow-up will be done. The following sections of this topical review are dedicated to the description and discussion of the current followup strategies after EVT of an intracranial aneurysm.
When to Follow-and for How Long?
To the best of our knowledge, there exists no guideline and no scientific data defining the optimal regime when and how long to follow-up. A large variety of schemes are used among different departments and different countries. The aneurysm's characteristics, the patient life expectancy, the device used to treat the aneurysm, and the patient psychology are the main points taken into account when proposing a particular scheme of follow-up. The optimal follow-up will balance avoidance of bleeding with minimizing unnecessary expense and patient anxiety.
Typically, the first follow-up after EVT is scheduled 3 to 6 months after the procedure with further follow-up tests in varying intervals depending on the department's regimen and the patient/aneurysm characteristics. Then, a classical scheme will include a 12-to 24-month follow-up and a midterm follow-up at 3 to 5 years. 10, 16 The post-EVT first year period is crucial because most recurrences occur during this period, justifying both imaging controls. 10, 16 The ideal frequency of examinations and length of follow-up is actually not determined, but more frequent follow-up may be indicated in patients harboring risk factors of recurrence (ie, ruptured aneurysms, large aneurysms, wide neck, and incomplete postoperative occlusion). 13, 14 The imaging modalities and intervals of follow-up can vary along the time depending on the degree of occlusion of the aneurysm and particularly if there is an evolution. Figure 1 proposes a classical follow-up scheme based on main data from the literature, with emphasis on the differences according to the degree of occlusion of the aneurysms (occlusion, residual neck, and residual aneurysm) and what to do in case of growing sac or neck. For patients followed up with noninvasive techniques (ie, magnetic resonance angiography [MRA]), the appearance or evolution of a small residual neck will lead to the realization of a concomitant digital subtraction angiography (DSA) to verify the diagnosis and ensure an accurate estimation of the size of the remnant. In case of good correlate, closer monitoring may be subsequently performed noninvasively.
About the question how long patients must be followed after coil embolization, recent data in the literature suggest that follow-up periods of 3 to 5 years may not be sufficient to detect relevant aneurysm recurrences. In a publication by Lecler et al 16 -including both a prospective cohort study and a meta-analysis-aneurysm recurrences between midterm (3-5 years after coiling) and long-term follow-up (>10 years after coiling) were detected in 12.4% of treated aneurysms. Risk factors for late aneurysm recurrence were an aneurysm size >10 mm, a grade 2 aneurysm (ie, residual neck) at 3-to 5-year follow-up MR (as graded by the modified Raymond Scale 18 ), and a previous retreatment ≤5 years after the first embolization. We can unreservedly recommend the conclusion of Lecler et al 16 that longer follow-up periods of ≥10 years or more should be considered in these patients.
Because of their relatively recent development, no data exist on the long-term (>10 years) stability of aneurysms treated by means of flow diverters or intrasaccular flow disruptors. Late recurrences should be unlikely in these cases because of neointimal coverage of the aneurysm neck along the metal surface; however, the longest published follow-up results are ≤56 months and 41 months for flow diverters 19 and the WEB device (Sequent Medical, Aliso Viejo, CA), 20 respectively. Data on long-term stability are needed for these treatment modalities.
Another fact that has to be considered when following up patients with treated aneurysms is the development of de novo aneurysms. De novo aneurysms in the long term were discovered in 4.4% in the study of Kemp et al 17 and in 9.1% of patients in the above-mentioned study by Lecler et al. 16 Although not so rare, de novo aneurysms may have a risk for subarachnoid hemorrhage that is comparatively higher than the risk associated with similarly sized, small, initially discovered unruptured saccular aneurysms. 17 Thus, 2 approaches exist, with some centers proposing a more intensive monitoring that can lead to the treatment in case of rapid increase in size, whereras others proposing a systematic treatment of the de novo aneurysm.
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How to Follow?
Digital Subtraction Angiography
DSA is the gold standard for the evaluation of aneurysmal occlusion after coiling. Because of its high spatial resolution with 3D imaging and dynamic information, DSA allows scoring recurrent flow in the aneurysm. Raymond et al 18 scale is the most widely used: class 1 means complete occlusion; class 2 means residual neck; and class 3 means residual aneurysm.
DSA also has the advantage of not being impaired by device-related artifacts, meaning that whatever the occlusion device used, coils, stent, or intrasacular flow disrupter, the analysis of aneurysmal residual flow remains accurate as to the device positioning and the artery permeability. 21, 22 However, DSA is an invasive procedure exposing the patient to complications such as cerebral thromboembolism (from silent microemboli to transient or permanent neurological deficit in 0.5% to 3% of procedures), contrast nephtotoxicity or anaphylactic reaction, ionizing radiation, and hematoma on the puncture site. 23 As neurological risks accumulate because of the required repeated procedures during the follow-up period, noninvasive imaging techniques are frequently preferred.
contrast-enhanced (CE) or as time-of-flight (TOF) MRA. TOF-MRA depicts inflow in the arteries without requiring gadolinium use. Common drawbacks are a lower sensitivity to slow and turbulent blood flow that is why a lower sensitivity for slowly perfused aneurysm remnants may occur. 24 Moreover, a subacute thrombus with high T1-weighted imaging signal intensity may simulate an intrasaccular residual flow. 25 Another disadvantage is that a high-resolution TOF-MRA takes several minutes to be acquired making TOF-MRA more prone to motion artifacts. On the contrary, the use of CE-MRA increases the costs of imaging and requires a contrast timing together with a narrow interval of scanning.
24-26
Coiled Aneurysms
As therapeutic consequences may derive from follow-up imaging, the diagnostic accuracy of MRA was demonstrated in comparison with DSA of reference in 5 main meta-analyses focused on coiled aneurysms ( Figure 1) . 24, [26] [27] [28] [29] Three of them compared TOF-MRA and CE-MRA 26,27,29 demonstrating that both are equally suitable for aneurysm surveillance, with high sensitivity and specificity values to detect aneurysm recurrence (Table 1) . Although aneurysm remnants might be missed on MRA, their small sizes usually do not require retreatment.
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About TOF-MRA, it was shown on a direct comparison that 3T high field offers a better detection of the recurrence than 1.5T field with a better interobserver agreement 31 although similar performance between both magnetic fields was previously shown on a larger cohort but comparing 2 different groups of patients.
32 With TOF-MRA, coils are visible and appear as a signal void created by artifacts because of platinum (which is absent or less visible with CE-MRA). 33 These slight artifacts did not hamper recurrence identification and were lower at 3T than at 1.5T, 31,32 because of the fact that higher-field strength provides a better signal:noise ratio and a superior spatial resolution.
About CE-MRA, a trend toward higher performance was observed at 3T
26,33 and with CE-MRA better able to distinguish aneurysm remnant from neck remnant than TOF-MRA. 33 Further data on this topic are needed. In clinical practice, there is no clear recommendation and various practices exist, from centers exclusively using 3T-MRA for follow-up to those using regular DSA. However, DSA is required in every case of aneurysm recurrence detected on MRA, potentially requiring retreatment.
Other Embolization Devices
A stent appears as a tiny endoluminal signal void, with artifacts originating from the markers or the stent material itself ( Figure 2 ). MR imaging of stents remains difficult because of a combination of magnetic susceptibility artifact and Faraday cage effect. These 2 artefacts may result in the appearance of occlusion or false stenosis of the artery in which the stent was deployed. 34, 35 Few studies assessed the value of MRA for noninvasive follow-up of aneurysms treated with stent-assisted coiling.
34,35 They mildly suggest that CE-MRA might be superior to TOF-MRA in these cases, as the latter seems to be more prone to artifacts from the stent, thus resulting in difficulties to evaluate the parent artery and the aneurysm neck.
The same holds true for flow diverter stents, which are composed of braided strands of cobalt chromium and platinum and 4 radio-opaque platinum markers. In a recent study on patients treated with flow diverter stents, Attali et al 36 found that at 3T, aneurysm recurrence can be detected using CE-MRA with a sensitivity of 83% and a specificity of 100% when compared with TOF-MRA with sensitivity and specificity values of 50% In clinical practice, imaging follow-up of patients with stents always requires at least 1 DSA examination, often performed between 6 and 12 months after the embolization, when stopping 1 antiplatelet therapeutic is considered. An MRA is simultaneously performed for further comparison in follow-up imaging. In case of in-stent stenosis or no good flow through the stent seen on MRA, a new DSA will be necessary to confirm or refute MRA findings. If the diagnosis of in-stent stenosis pattern is confirmed, a close follow-up with a yearly DSA (or more in case of neurological symptoms) will monitor potential modifications. Different evolution depending on the pathomechanism of the stenosis can be observed and will determine further monitoring. Clot deposits into the stent mesh will quickly disappear after the addition of a supplementary antiaggregant (leading to space the follow-up), whereas in the case of endothelial hyperplasia, the stenosis will continue to increase (leading to pursue the close follow-up).
Drawing a parallel between the WEB device and stents of equivalent composition, it seems reasonable that the same artifacts will affect MR images. One study assessed CE-MRA value on 15 patients treated with the WEB device, 38 which is composed of nitinol with distal platinum markers. It concluded that CE-MRA failed to identify 3 out of 5 inadequately occluded aneurysms. Consequently, DSA remains the method of choice to follow aneurysms treated with the WEB device. 22 ,39 A CE-MRA can be obtained in conjunction with DSA to serve as a baseline measure.
Computed Tomography Angiography
Computed tomography angiography (CTA) is a widely available, low-cost, and noninvasive method with short examination times, but imaging of coiled aneurysm is severely hampered by beam-hardening artifacts caused by the platinum coil mass. Thus, CTA is not suitable for coiled aneurysm follow-up, and DSA remains required in case of magnetic resonance imaging contraindication.
Few data exist on the value of CTA for the follow-up of aneurysms treated with stents, flow diverters, and flow disrupters, and if CTA is to be an alternative to DSA for surveillance and restenosis detection, the utility of this method in these instances will have to be determined. Studies focused on the agreement between CTA and DSA for in-stent evaluation. 40 However, 64 multidetector CTA suffered from less artifacts induced by stents than TOF-MRA at 3T. 41 In the near future, the development of novel metal artifactreduction algorithms 42 or use of dual-energy CT may increase CTA significance. 43 Still, flat-panel detector CTA using intra-arterial or preferentially intravenous contrast medium (for noninvasivity) is increasingly used for visualization of stent devices and aneurysm lumen analysis. 44 It allows assessment of wall apposition and kinking of stents, along with intrasacular flow, with highresolution directly in the angiography suite. Applied to WEB, it allows determination of the aneurysm occlusion and of the device position and deployment. 45 Data are scarce on this topic, and controlled studies with larger patient numbers are needed to assess both CTA +++ indicates excellent accuracy, recommended modality for routine follow-up; ++, moderate accuracy, can be used in specific cases; +, low accuracy, limited place in routine actually; ? not evaluated; CE-MRA, contrast-enhanced magnetic resonance angiography; CTA, computed tomographic angiography; DSA, digital subtraction angiography; and TOF, time-of-flight. 
Other Techniques
Plain skull x-rays and transcranial color-coded duplex sonography have also been proposed for the detection of aneurysm recurrence after coil embolization.
46,47 Radiographs evaluate the compaction of the coil mass in comparison with a baseline image. Although it seems to be an effective and quick test, it was shown to be less accurate than MRA. 46 For its part, transcranial sonography had a moderate accuracy even for aneurysms with extensive refilling (sensitivity 45% and specificity 100%). 47 Actually, these interesting techniques have a limited place in the follow-up of intracranial aneurysms.
A summary of the diagnostic accuracies of imaging modalities for follow-up in regard to the device used for treatment is displayed in Table 2 .
Conclusions
Imaging follow-up of intracranial aneurysms treated by endovascular means is important for the detection of situations at risk of bleeding (aneurysm recurrence and de novo aneurysm).
Although very important during the first year, it seems useful to pursue it on the mid and long term. There exist no guidelines on the frequency of monitoring and imaging modality to adopt and the monitoring is adapted on a case-by-case basis. MRA is a suitable modality after coil embolization, but DSA remains necessary for evaluating other devices.
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